Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Erosive esophagitis associated with GERD
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Healing of duodenal ulcers
* *Helicobacter pylori* eradication (in combination therapy)
### Adult Dosing
* **Erosive esophagitis/GERD:** 40 mg orally or intravenously once daily. Duration typically 4-8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally or intravenously twice daily. Doses may be titrated up to 240 mg daily divided into doses.
* ***H. pylori* eradication:** 40 mg orally twice daily for 7-14 days in combination with antibiotics (e.g., amoxicillin and clarithromycin, or metronidazole and clarithromycin).
### Pediatric Dosing
* **Erosive esophagitis (GERD):**
* 1-5 years: 10 mg orally once daily.
* 5-12 years: 20 mg orally once daily.
* 12-16 years: 40 mg orally once daily.
* Dosing for pathological hypersecretory conditions is not established in pediatrics.
### Dose Adjustments
No dose adjustment is typically needed for hepatic or renal impairment.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less Common: Rash, urticaria, myalgia, arthralgia.
Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia, vitamin B12 deficiency, potential for increased risk of pneumonia.
### Key Drug Interactions
* **Antiretrovirals (e.g., rilpivirine, atazanavir):** Decreased absorption of antiretrovirals due to increased gastric pH. Separate administration or avoid.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider dose reduction or interruption of pantoprazole.
* **CYP2C19 substrates (e.g., clopidogrel):** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential for reduced efficacy of clopidogrel.
* **Iron salts and azole antifungals:** Decreased absorption due to increased gastric pH.
### Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Consider monitoring serum magnesium levels, especially with prolonged use (>3 months) or concurrent diuretic use.
* Monitor for signs of bone fracture.
* Monitor for signs and symptoms of vitamin B12 deficiency with prolonged use.
### Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal.
* For IV administration, reconstitute and dilute as per manufacturer instructions. Do not administer IV pantoprazole with other medications in the same IV line.
* Long-term PPI use is associated with increased risks of fractures, C. difficile infection, and vitamin B12 deficiency; use the lowest effective dose for the shortest duration necessary.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols before making any therapeutic decisions.
